Nephrology Doctors in Topeka, KS Accepting Medicare

8 Nephrology doctors found. Showing 1 - 8

Dr. Dennis Charles Artzer, MD Internal Medicine - Nephrology Medicare: Not Enrolled in Medicare Practice Location: 631 Sw Horne, Suite 420, Topeka, KS 66606 Phone: 785-232-4545    Fax: 785-232-0555

Dr. Robert D Porter, M.D. Internal Medicine - Nephrology Medicare: Not Enrolled in Medicare Practice Location: 901 Sw Garfield Ave, Topeka, KS 66606 Phone: 785-354-9591    Fax: 785-368-0478

Lakshmi K Duvvur, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 823 Sw Mulvane St, Topeka, KS 66606 Phone: 785-354-9591

Dr. Scott C Solcher, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 823 Sw Mulvane St, Topeka, KS 66606 Phone: 785-354-9591

Phillip J Olsson, MD Internal Medicine - Nephrology Medicare: Medicare Enrolled Practice Location: 200 Sw Frazier Cir, Topeka, KS 66606 Phone: 785-232-2044    Fax: 785-232-5567

Thomas W Alderson, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 823 Sw Mulvane St, Topeka, KS 66606 Phone: 785-354-9591

Dr. Keelyn L Ericson, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 823 Sw Mulvane St, Topeka, KS 66606 Phone: 785-354-9591

Vamsee Priya Marina, MD Internal Medicine - Nephrology Medicare: Not Enrolled in Medicare Practice Location: 823 Sw Mulvane St, Topeka, KS 66606 Phone: 785-354-9591

News Archive

Genzyme third quarter revenue increases to $1.0 billion

Genzyme Corp. today reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter. Earnings growth in the third quarter was also driven by strong revenue from Lumizyme™ (alglucosidase alfa) and cost reduction measures.

Health Canada grants Osiris Priority Review for Prochymal NDS

Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.

ProteinSimple introduces revolutionary re-invention of Western blot

ProteinSimple today introduced Wes, another revolutionary re-invention of the Western blot. Wes is the bold evolution of the popular Simple Western family of instruments, delivering simplicity and performance like no product before it. With just 30 minutes of sample prep, Wes will analyze up to 25 samples in under 3 hours and he will do it all for less than the price of a high-end Western imager.

Frequent nighttime hot flashes may trigger mild depression symptoms during menopause

A woman's perception that she is experiencing a high number of nighttime hot flashes can trigger mild symptoms of depression during menopause, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

Study identifies six patterns of child and stepparent relationship development

More than 40 percent of Americans have at least one step relative, according to a recent Pew Center study. Relationships between stepchildren and stepparents can be complicated, especially for children.

Read more Medical News

› Verified 7 days ago